Skip to main content
    K

    Kestra Medical Technologies, Ltd. Common Stock (KMTS)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $27.97
    -0.67 (-2.34%)

    Market Cap: $1.71B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Kestra Medical Technologies, Ltd. Common Stock (KMTS) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Kestra Medical Technologies, Ltd. Common Stock (KMTS) to earn -$2.45 per share in the fiscal year ending Apr 30, 2027, on revenue of $140.85M. Of 9 analysts, 8 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Apr 30, 2027 were revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 1.89, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 89% of the ratings.

    RatingAnalystsShare
    Strong Buy222.2%
    Buy666.7%
    Hold111.1%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    9

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 39.1%.

    Fiscal year ending Apr 30, 2027
    -$2.45
    EPS consensus, revenue $140.85M
    Fiscal year ending Apr 30, 2028
    -$2.06
    EPS consensus, revenue $195.99M
    Next report
    Dec 11, 2026
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Apr 30, 2027-$2.45-$2.46 to -$2.442$140.85M$140.40M to $141.04M9
    Apr 30, 2028-$2.06-$2.06 to -$2.052$195.99M$190.22M to $200.54M9

    Quarterly Estimates

    The EPS consensus rises from -$0.58 for the quarter ending Jan 31, 2027 to -$0.54 for the quarter ending Apr 30, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Jan 31, 2027-$0.58-$0.58 to -$0.572$35.49M$35.00M to $36.00M9
    Apr 30, 2027-$0.54-$0.60 to -$0.5411$43.19M$40.08M to $45.15M11

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 0 upward and 4 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Apr 30, 202702
    Fiscal year ending Apr 30, 202801
    Quarter ending Jan 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Apr 30, 2027 has worsened from -$2.31.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Apr 30, 2027-$2.45-$2.45-$2.45-$2.31-$2.31N/A
    Fiscal year ending Apr 30, 2028-$2.06-$2.06-$2.06-$2.02-$2.02N/A
    Quarter ending Jan 31, 2027-$0.58-$0.58-$0.58-$0.57-$0.57N/A

    Frequently Asked Questions About KMTS

    What is the KMTS stock forecast?

    Consensus analyst estimates put Kestra Medical Technologies, Ltd. Common Stock's EPS at -$2.45 for the fiscal year ending Apr 30, 2027, on revenue of $140.85M. The consensus rating from 9 analysts is Buy.

    How do analysts rate KMTS stock?

    Of 9 analysts covering Kestra Medical Technologies, Ltd. Common Stock, 2 rate it Strong Buy, 6 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from KMTS next year?

    For the fiscal year ending Apr 30, 2027, the consensus EPS estimate is -$2.45, with estimates from -$2.46 to -$2.44 from 2 analysts. For the fiscal year ending Apr 30, 2028, the consensus EPS estimate is -$2.06, with estimates from -$2.06 to -$2.05 from 2 analysts.

    What revenue do analysts expect from Kestra Medical Technologies, Ltd. Common Stock next year?

    For the fiscal year ending Apr 30, 2027, the consensus revenue estimate is $140.85M, with estimates from $140.40M to $141.04M. For the fiscal year ending Apr 30, 2028, the consensus revenue estimate is $195.99M, with estimates from $190.22M to $200.54M.

    How many analysts cover KMTS?

    9 analysts rate Kestra Medical Technologies, Ltd. Common Stock stock, and 2 analysts estimate its EPS for the fiscal year ending Apr 30, 2027.